P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
Christopoulou, A, Marmé, F, Oaknin, A, Lorusso, D, Safra, T, Lindahl, G, Chudecka-Glaz, A, Ciuleanu, T, Collins, DC, Demirkiran, F, Lifrenko, I, Van Gorp, T, Coleman, RL, Fujiwara, K, Oza, AM, Westin, SN, O’Malley, DM, Herzog, TJ, Eskander, R, Wilson, M, Argire, S, Grechko, N, McNeish, IA, Monk, BJ, Kristeleit, RS
Published in International journal of gynecological cancer (01.11.2019)
Published in International journal of gynecological cancer (01.11.2019)
Get full text
Journal Article